{
    "Question": "Sana Health CES 2024 product highlight and specification",
    "Summary": "Sana Health\n\nProduct 1: SC255\n\n - HIP-modified, BCMA-targeted allogeneic CAR T therapy\n - Expected IND filing in 2024 for multiple myeloma treatment\n - BCMA validated as a target for autologous CAR T therapy in relapsed/refractory multiple myeloma",
    "Summary_cn": "Sana Health\n\n产品1：SC255\n\n- 经过HIP修饰，以BCMA为靶点的异基因CAR T疗法\n- 预计2024年递交IND申请，用于治疗多发性骨髓瘤\n- BCMA已证实为自体CAR T疗法在复发/难治性多发性骨髓瘤中的靶点"
}